Peringkat dalam Saham
#41419
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing... Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer diagnosis, as well as the Guanylyl Cyclase C (GCC) marker and the Previstage GCC colorectal cancer staging test, both vital for patients with colorectal cancer. They also offer PCP, a multi-marker diagnostic for prostate cancer. In addition to these tests, Diagnocure provides specialized services such as gene expression and copy number variation analysis, mutation detection, SNP genotyping, and comprehensive platform and laboratory environmental support. Established in 1994 as 9342-8530 Québec Inc. and previously known as DiagnoCure Inc., the company is headquartered in Quebec, Canada.
Harga Saham
$0.0001
Terakhir disinkronkan: 2025-06-11
Kapitalisasi Pasar
$21.52K
Perubahan (1 tahun)
0.00%
Perdagangan Diagnocure, Inc. (DGCRF)
Harga DGCRF dengan kapitalisasi pasar B
Kapitalisasi pasar dari Diagnocure, Inc.(DGCRF)
Kapitalisasi Pasar: $21.52K
Per August 2026, Diagnocure, Inc. memiliki kapitalisasi pasar sebesar $21.52K. Ini menjadikan Diagnocure, Inc. sebagai perusahaan 41419th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Diagnocure, Inc. dari 2012 hingga 2026
DGCRF dibandingkan dengan 5 teratas stocks paling populer
| Harga DGCRF |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.383T
|
+25,015,610,773.61%
|
|
|
|
|
$4.423T
|
+20,554,791,738.93%
|
|
|
|
|
$4.160T
|
+19,332,571,457.07%
|
|
|
|
|
$3.663T
|
+17,022,866,242.94%
|
|
|
|
|
$2.891T
|
+13,435,077,945.54%
|
